AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25363789 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-targeted in-patient education (group 2)
Number of subjects: 198
Study 25363789 — intervention group
Group type: COMPARATOR
Intervention: Standard education (group 1)
Number of subjects: 198
Study 22392456 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (first-step treatment)
Number of subjects: 727
Study 22392456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion, sertraline, or extended-release venlafaxine (second-step treatment)
Number of subjects: 727
Study 20515209 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSY (Information + Psychosocial Competence = Protection)
Number of subjects: 1484
Study 20515209 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSY
Number of subjects: 1484
Study 20515209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1484
Study 18036121 — intervention group
Group type: EXPERIMENTAL
Intervention: New leaflet
Number of subjects: 126
Study 18036121 — intervention group
Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 126
Study 16136287 — intervention group
Group type: EXPERIMENTAL
Intervention: Quixil sealant
Number of subjects: 20
Study 16136287 — intervention group
Group type: COMPARATOR
Intervention: Kaltostat (control)
Number of subjects: 20
Study 12036528 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 14
Study 12036528 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 12036528 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil withdrawal
Number of subjects: 14
Study 10207807 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 1148
Study 10207807 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cirrhotic type C patients not receiving interferon)
Number of subjects: 1148
Study 7599914 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 23
Study 7599914 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 23
Study 2221406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 1178
Study 2221406 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 1178
Study 93297 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-globulin 16 Merieux (1 ml/kg)
Number of subjects: 8
Study 93297 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 31118057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 4 J/cm2
Number of subjects: 97
Study 31118057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 97
Study 28168199 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 31
Study 28168199 — intervention group
Group type: COMPARATOR
Intervention: Control group (139 patients who underwent CE)
Number of subjects: 31
Study 26736728 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 26736728 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 0
Study 23807528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 119
Study 22046394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine (TDF-FTC), n = 178
Number of subjects: 303
Study 22046394 — intervention group
Group type: COMPARATOR
Intervention: Abacavir-lamivudine (ABC-3TC), n = 179
Number of subjects: 303
Study 19934423 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS with intravenous drug administration
Number of subjects: 851
Study 19934423 — intervention group
Group type: COMPARATOR
Intervention: ACLS without intravenous drug administration
Number of subjects: 851
Study 16476841 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO), 10,000 U three times weekly s.c.
Number of subjects: 0
Study 16476841 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 12771010 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 391
Study 12771010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 10677157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin group (maintaining a whole blood heparin concentration of 3 mg/kg)
Number of subjects: 2
Study 10677157 — intervention group
Group type: COMPARATOR
Intervention: ACT group (maintaining an ACT >400 s)
Number of subjects: 2
Study 9116534 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline certification program for cesarean section deliveries
Number of subjects: 366246
Study 9116534 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat cesareans
Number of subjects: 366246
Study 9116534 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cesareans
Number of subjects: 366246
Study 9116534 — intervention group
Group type: COMPARATOR
Intervention: Guideline implementation date
Number of subjects: 366246
Study 8157720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction at 10 Cal/kg lean body mass.day
Number of subjects: 7
Study 3345633 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-absorptive state in healthy subjects
Number of subjects: 28
Study 3345633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state in healthy subjects
Number of subjects: 28
Study 3345633 — intervention group
Group type: COMPARATOR
Intervention: Patients with muscular dystrophy in fed state
Number of subjects: 28
Study 3345633 — intervention group
Group type: COMPARATOR
Intervention: Patients with myotonic dystrophy in post-absorptive state
Number of subjects: 28
Study 29758175 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instructions
Number of subjects: 120
Study 29758175 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instructions
Number of subjects: 120
Study 29758175 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal plus written instructions
Number of subjects: 120
Study 29758175 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal instructions)
Number of subjects: 120
Study 24521107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxantel pamoate (20 mg/kg) plus albendazole (400 mg)
Number of subjects: 458
Study 24521107 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole (500 mg)
Number of subjects: 458
Study 24521107 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg)
Number of subjects: 458
Study 22422104 — intervention group
Group type: COMPARATOR
Intervention: Spousal caregiver
Number of subjects: 374
Study 22422104 — intervention group
Group type: COMPARATOR
Intervention: Non-spousal caregiver
Number of subjects: 374
Study 20715734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target glycaemic control: 4.4 to 6.1 mmol/l)
Number of subjects: 523
Study 20715734 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (target control: 10.0 to 11.1 mmol/l)
Number of subjects: 523
Study 20715734 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic fluctuation (mean difference between highest and lowest daily blood glucose)
Number of subjects: 523
Study 18023151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of parenteral veterinary preparation of ivermectin
Number of subjects: 42
Study 18023151 — intervention group
Group type: COMPARATOR
Intervention: 7-day course of oral albendazole 800 mg daily
Number of subjects: 42
Study 15738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Late transabdominal chorionic villus sampling (CVS)
Number of subjects: 3698
Study 15738029 — intervention group
Group type: COMPARATOR
Intervention: Early amniocentesis
Number of subjects: 3698
Study 15738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis with no placental penetration
Number of subjects: 3698
Study 15738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis with placental penetration
Number of subjects: 3698
Study 15738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Late CVS
Number of subjects: 3698
Study 12973169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial filters (BF)
Number of subjects: 230
Study 12973169 — intervention group
Group type: COMPARATOR
Intervention: No bacterial filters (Control)
Number of subjects: 230
Study 10619727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg) daily for 14 days
Number of subjects: 316
Study 10619727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 8949765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron therapy alone or in combination with photons
Number of subjects: 906
Study 8949765 — intervention group
Group type: COMPARATOR
Intervention: Photons only
Number of subjects: 906
Study 2023603 — intervention group
Group type: EXPERIMENTAL
Intervention: f/VT ratio
Number of subjects: 100
Study 2023603 — intervention group
Group type: EXPERIMENTAL
Intervention: Plmax
Number of subjects: 100
Study 2023603 — intervention group
Group type: EXPERIMENTAL
Intervention: CROP index
Number of subjects: 100
Study 2023603 — intervention group
Group type: EXPERIMENTAL
Intervention: VE
Number of subjects: 100
Study 7282596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (100 or 400 units/day orally for 4 weeks)
Number of subjects: 12
Study 7282596 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (0.01 mg/100 g, IP) with vitamin E (1000 units/kg IM for 7 days) in rats
Number of subjects: 12
Study 31785442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait disorder
Number of subjects: 160
Study 31785442 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoclonus
Number of subjects: 160
Study 31303750 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive intervention (HCI) for 12 weeks
Number of subjects: 57
Study 31303750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 28077140 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (IND) + Glycopyrronium (GLY)
Number of subjects: 78
Study 28077140 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol (IND)
Number of subjects: 78
Study 26025128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCS) - short-term oral prednisone bursts during acute asthma exacerbations
Number of subjects: 489
Study 23250820 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 0
Study 23250820 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection techniques
Number of subjects: 0
Study 21225278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAH
Number of subjects: 25
Study 21225278 — intervention group
Group type: COMPARATOR
Intervention: Patients with PAH (OS(-))
Number of subjects: 25
Study 21225278 — intervention group
Group type: COMPARATOR
Intervention: OS(+) patients
Number of subjects: 25
Study 19791639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low autonomy (LA) instructional climate
Number of subjects: 117
Study 19791639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery motivational climate (MMC) instructional climate
Number of subjects: 117
Study 19791639 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 117
Study 17645252 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with functional training
Number of subjects: 90
Study 17645252 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 90
Study 17645252 — intervention group
Group type: COMPARATOR
Intervention: Functional training
Number of subjects: 90
Study 14747807 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release acetaminophen preparation (75 mg/kg) with whole bowel irrigation
Number of subjects: 10
Study 14747807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no whole bowel irrigation)
Number of subjects: 10
Study 11878526 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml of 7.5 mg ml(-1) ropivacaine (18.75 mg)
Number of subjects: 104
Study 11878526 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml of 10 mg ml(-1) ropivacaine (25 mg)
Number of subjects: 104
Study 9492256 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of itraconazole 40‐mg/mL oral suspension
Number of subjects: 10
Study 9492256 — intervention group
Group type: COMPARATOR
Intervention: Four 100‐mg itraconazole capsules
Number of subjects: 10
Study 9492256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole from the suspension
Number of subjects: 10
Study 9492256 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyitraconazole from the capsules
Number of subjects: 10
Study 7987084 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop excision (n = 38)
Number of subjects: 90
Study 7987084 — intervention group
Group type: COMPARATOR
Intervention: Cold-knife conization (n = 52)
Number of subjects: 90
Study 2839280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin 60 to 75 mg/m2 at 3-week intervals
Number of subjects: 106
Study 2839280 — intervention group
Group type: COMPARATOR
Intervention: No antitumor therapy
Number of subjects: 106
Study 31856675 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPP technique
Number of subjects: 300
Study 31856675 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 300
Study 31856675 — intervention group
Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 300
Study 31366355 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, electronic health record (EHR)-linked clinical decision support (CDS) system for cancer prevention and screening recommendations.
Number of subjects: 28
Study 31366355 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized training, pilot testing, implementation plans, and post-implementation efforts.
Number of subjects: 28
Study 28385642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPR (LUCAS)
Number of subjects: 757
Study 28385642 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 757
Study 24814388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) plus ribavirin (1000/1200 mg/day) for 24 weeks
Number of subjects: 66
Study 24814388 — intervention group
Group type: COMPARATOR
Intervention: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) without ribavirin (Arm B) for 24 weeks
Number of subjects: 66
Study 23911183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy with threshold suspend
Number of subjects: 0
Study 23911183 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (control)
Number of subjects: 0
Study 21744200 — intervention group
Group type: EXPERIMENTAL
Intervention: Handpiece removal of mini-implants
Number of subjects: 25
Study 21744200 — intervention group
Group type: COMPARATOR
Intervention: Manual removal of mini-implants
Number of subjects: 25
Study 21744200 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection
Number of subjects: 25
Study 21744200 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic injection
Number of subjects: 25
Study 18096918 — intervention group
Group type: EXPERIMENTAL
Intervention: CICS Provided
Number of subjects: 226
Study 18096918 — intervention group
Group type: COMPARATOR
Intervention: No CICS Provided
Number of subjects: 226
Study 16484892 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (20 mg)
Number of subjects: 10
Study 16484892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14574783 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose paracetamol (6 g daily)
Number of subjects: 2500
Study 14574783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 11086269 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464
Study 11086269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 464
Study 11086269 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 464
Study 9411418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only (25 kcal/kg b.w.)
Number of subjects: 42
Study 9411418 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy (mean daily dose 18 +/- 8 U)
Number of subjects: 42
Study 1551536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms single dose)
Number of subjects: 17
Study 1551536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms/day for 1 week)
Number of subjects: 17
Study 1551536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1551536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms single dose and 150 micrograms/day for 1 week)
Number of subjects: 17
Study 2864845 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 15
Study 2864845 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 15
Study 30266522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (40 minutes, 3-5 times per week for 24 weeks)
Number of subjects: 68
Study 30266522 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 68
Study 26659714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam HR measurements in early keratoconus (Krumeich stage 1 or 2)
Number of subjects: 96
Study 26659714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam HR measurements in advanced keratoconus (Krumeich stage >2)
Number of subjects: 96
Study 26659714 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratometric measurements on Pentacam HR
Number of subjects: 96
Study 26659714 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in K1, K2 or Kmax of more than 1 dioptre in early keratoconus
Number of subjects: 96
Study 25046070 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg/d)
Number of subjects: 40
Study 25046070 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg) plus montelukast (10 mg)
Number of subjects: 40
Study 22967772 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 8 weeks
Number of subjects: 205
Study 20603454 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset conduct disorder (EO-CD)
Number of subjects: 75
Study 20603454 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescence-onset conduct disorder (AO-CD)
Number of subjects: 75
Study 20603454 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 17393438 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200-2,400 mg/day)
Number of subjects: 150
Study 17393438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15741834 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretion rate of s‐IgA
Number of subjects: 100
Study 15741834 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐IgA
Number of subjects: 100
Study 15741834 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of URTI
Number of subjects: 100
Study 12049678 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (24-hour infusion starting 6-18 hours after CABG at an average dose of 67 +/- 7 microg/kg/min)
Number of subjects: 50
Study 12049678 — intervention group
Group type: COMPARATOR
Intervention: Oral beta-blockers only (starting on postoperative day 1)
Number of subjects: 50
Study 9528875 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-film series (occipito mental, occipito mental 30 and lateral)
Number of subjects: 200
Study 9528875 — intervention group
Group type: COMPARATOR
Intervention: Two-film series (lateral excluded)
Number of subjects: 200
Study 8535804 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary node sampling
Number of subjects: 417
Study 8535804 — intervention group
Group type: COMPARATOR
Intervention: Axillary clearance
Number of subjects: 417
Study 2200924 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (BNZ)
Number of subjects: 20
Study 2200924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4561679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (24 mg or 48 mg daily)
Number of subjects: 21
Study 4561679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31759092 — intervention group
Group type: EXPERIMENTAL
Intervention: Generativity writing condition (6-week intervention)
Number of subjects: 73
Study 31759092 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition (neutral, descriptive writing)
Number of subjects: 73
Study 31240303 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO group)
Number of subjects: 44
Study 31240303 — intervention group
Group type: COMPARATOR
Intervention: Control (CON group)
Number of subjects: 44
Study 28266318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 60
Study 28266318 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 26094782 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day workshop plus educational material
Number of subjects: 70
Study 26094782 — intervention group
Group type: COMPARATOR
Intervention: Written educational material alone
Number of subjects: 70
Study 23461482 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape educational programme
Number of subjects: 70
Study 23461482 — intervention group
Group type: COMPARATOR
Intervention: Routine training
Number of subjects: 70
Study 22092124 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple prophylaxis (dexamethasone 8 mg IV, ondansetron 4 mg IV, droperidol 0.625 mg IV)
Number of subjects: 157
Study 22092124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone added to ondansetron and droperidol
Number of subjects: 157
Study 22092124 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron and droperidol (with or without dexamethasone)
Number of subjects: 157
Study 20131551 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem hydrochloride ointment (2%)
Number of subjects: 102
Study 20131551 — intervention group
Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate ointment (0.2%)
Number of subjects: 102